A A Melcher
Overview
Explore the profile of A A Melcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
879
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula J, White C, et al.
Gene Ther
. 2012 Aug;
20(5):521-8.
PMID: 22895509
Oncolytic reovirus is currently under active investigation in a range of tumour types. Early phase studies have shown that this agent has modest monotherapy efficacy and its future development is...
12.
Simpson G, Horvath A, Annels N, Pencavel T, Metcalf S, Seth R, et al.
Br J Cancer
. 2012 Jan;
106(3):496-507.
PMID: 22240799
Background: There are still no effective treatments for superficial bladder cancer (SBC)/non-muscle invasive bladder cancer. Following treatment, 20% of patients still develop metastatic disease. Superficial bladder cancer is often multifocal,...
13.
Donnelly O, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, et al.
Gene Ther
. 2011 Dec;
20(1):7-15.
PMID: 22170342
Oncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of human melanoma....
14.
Win S, McMillan D, Errington-Mais F, Ward V, Young S, Baird M, et al.
Br J Cancer
. 2011 Dec;
106(1):92-8.
PMID: 22134504
Background: Tumour cell lysates are an excellent source of many defined and undefined tumour antigens and have been used clinically in immunotherapeutic regimes but with limited success. Methods: We conjugated...
15.
West E, Scott K, Jennings V, Melcher A
Br J Cancer
. 2011 Aug;
105(6):787-95.
PMID: 21847125
Background: Optimal cellular immunotherapy for cancer should ideally harness both the innate and adaptive arms of the immune response. Lymphokine-activated killer cells (LAKs) can trigger early innate killing of tumour...
16.
Donnelly O, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R, et al.
Curr Pharm Biotechnol
. 2011 Jul;
13(9):1834-41.
PMID: 21740364
There has been interest in using viruses to treat cancer for over a century. Recent clinical efforts, driven on by significant preclinical advances, have focussed on the safety of using...
17.
Ilett E, Prestwich R, Melcher A
Expert Opin Biol Ther
. 2010 Feb;
10(3):369-79.
PMID: 20132058
Importance Of The Field: Dendritic cells (DC) are a clear choice for use in cancer immunotherapy, and much research has focused on generating DC for clinical use. Although DC therapy...
18.
Ilett E, Prestwich R, Kottke T, Errington F, Thompson J, Harrington K, et al.
Gene Ther
. 2009 Mar;
16(5):689-99.
PMID: 19282847
Reovirus is a naturally occurring oncolytic virus currently in early clinical trials. However, the rapid induction of neutralizing antibodies represents a major obstacle to successful systemic delivery. This study addresses,...
19.
Agrawal V, Copeland K, Barbachano Y, Rahim A, Seth R, White C, et al.
Gene Ther
. 2008 Sep;
16(1):78-92.
PMID: 18784747
Transfer of healthy autologous tissue as a microvascular free flap facilitates reconstruction during ablative cancer surgery. In addition to filling surgical defects, free flaps might concentrate viral vectors at the...
20.
Errington F, White C, Twigger K, Rose A, Scott K, Steele L, et al.
Gene Ther
. 2008 Apr;
15(18):1257-70.
PMID: 18401435
Reovirus is a promising unmodified double-stranded RNA (dsRNA) anti-cancer oncolytic virus, which is thought to specifically target cells with activated Ras. Although reovirus has been tested in a wide range...